Dr David Lepp

06/20/2026

10/26/2021

05/08/2021

https://www.nature.com/articles/s41577-020-00458-y?utm_source=pocket-app&utm_medium=share

"Given the lack of self-reactivity seen with the majority of SARS-CoV-2-neutralizing monoclonal antibodies, the development of efficacious and safe vaccines is clearly possible. However, ongoing vaccination trials should closely investigate the induction of potential tissue-reactive antibodies and related clinical signs."

Neurological symptoms are increasingly being observed in patients with COVID-19; this Comment article considers whether cross-reactive antibodies might contribute to the pathology associated with SARS-CoV-2 infection.

05/08/2021

https://www.bmj.com/content/371/bmj.m4347/rr-6?utm_source=pocket-app&utm_medium=share

"In the understandable socioeconomic rush towards mass vaccination without longer-term safety testing, it would seem that an essential stage in any vaccine licensing process should involve careful analysis of the human proteome against vaccine peptide sequences. This should minimize the risks both of acute autoimmune reactions to inoculation and future chronic autoimmune pathology"

Article Related content Article metrics Rapid responses Response Rapid Response: Could COVID-19 mRNA vaccines cause autoimmune diseases? Dear Editor, Mass vaccination offers the best exit strategy from the COVID-19 pandemic. Pfizer/BioNTech's recent announcement, therefore, is encouraging.[1] Their....

01/23/2021

https://www.frontiersin.org/articles/10.3389/fimmu.2020.617089/full?fbclid=IwAR3GF3jJ4B_7oC02wskuueuTScVDair-f6hnpt13f32yWEmO2V6yCC_M3nQ

We sought to determine whether immune reactivity occurs between anti-SARS-CoV-2 protein antibodies and human tissue antigens, and whether molecular mimicry between COVID-19 viral proteins and human tissues could be the cause. We applied both human monoclonal anti-SARS-Cov-2 antibodies (spike protein...

05/13/2020

Answers to your important questions based on science, not politics or belief systems: